Methotrexate and Fluorouracil Toxicities: A Collaborative Practice Approach to Prevention and Treatment


To earn credit, a pre-test is required. Click here to access activity pre-test:

If you do not want to earn credit but want to view the video, read the activity overview below.



Activity Overview

It is required you read the activity overview. Once you have scrolled to the end, click to confirm, and you will be able to watch the video.

Methotrexate and Fluorouracil Toxicities: 
A Collaborative Practice Approach to Prevention and Treatment

Filmed on October 31, 2014
at JADPRO Live at APSHO 2014

A continuing education activity for nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians

 

Meniscus Educational Institute
3131 Princeton Pike
Building 1, Suite 205

Lawrenceville
, NJ 08648
Voice: 609-246-5000
Fax: 631-449-7969
E-mail: mthompson@meniscusedu.com
Internet: www.meniscus.com

Advanced Practitioner Society of Hematology and Oncology
3131 Princeton Pike
Building 1, Suite 205

Lawrenceville
, NJ 08648
Voice: 609-832-3000
Fax: 610-834-8856
E-mail: Sandra@apsho.org

© 2014, Meniscus Educational Institute. All rights reserved.

 

 

This activity is supported by an unrestricted educational grant from BTG International.

 

Faculty

Christopher J. Campen, PharmD, BCPS, BCOP
Arizona Cancer Center, University of Arizona

 

Wendy H. Vogel, MSN, FNP, AOCNP®
Wellmont Cancer Center

 

Julie M. Vose, MD, MBA
University of Nebrasksa Medical Center

 

Activity Rationale and Purpose

The activity will focus on the prevention and management of methotrexate and fluorouracil-related toxicities, especially with regard to proper dosing, the current standard of care, collaborative models of assessment and monitoring, and continued high levels of supportive care. The symposium will also cover expanded access programs, including their purpose, benefits, and potential concerns. This session will be presented with a series of case studies. Advanced practitioner and physician roundtable participants will be given the opportunity to discuss the cases from the perspective of each of their roles in collaborative practice and the importance of the interprofessional approach. The goal is to provide the tools healthcare professionals need to expand delivery of state-of-the-art medical care, improve patient outcomes, and enhance the quality of life in patients with cancer, as well as reduce the barriers impacting the integration of therapies into practice and support adherence to current guidelines.

Intended Audience

The activity’s target audience will consist of nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

Learning Objectives

After completing this educational activity, participants should be able to:

  • Summarize the effects of methotrexate (MTX)- and fluorouracil (5-FU)-induced toxicities on managing cancer
  • Describe the appropriate strategies for managing MTX- and 5-FU-induced toxicities
  • Discuss collaborative practice initiatives for managing MTX- and 5-FU-induced toxicities
  • Become familiar with the clinical considerations regarding the use of glucarpidase for MTX toxicity and uridine triacetate for 5-FU overexposure
  • Review the most recent FDA guidelines on expanded access programs and their effect on clinical practice

Continuing Education

Statement of Credit—Participants who successfully complete this activity (including completion of the post-test with a passing score of at least 70% and evaluation form) will receive a statement of credit.

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Meniscus Educational Institute and Advanced Practitioner Society for Hematology and Oncology (APSHO) and JADPRO. The Meniscus Educational Institute is accredited by the ACCME to provide continuing medical education for physicians.

The Meniscus Educational Institute designates this enduring material (271.011-1420-MI) for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

This activity (271.011-1420-NI) for 0.75 contact hours is provided by the Meniscus Educational Institute.

The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Pharmacists

The knowledge-based accredited education lectures are intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Meniscus Educational Institute.

The Meniscus Educational Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to this program, for 0.75 contact hours, is 0429-9999-14-020-H01-P.

Important Notice Concerning Pharmacy Credits:  As of January 1, 2013, a central electronic repository for CPE information will be implemented nationally to enable state boards of pharmacy to efficiently verify CE completion. During registration for any ACPE-accredited program, you will be required to provide a valid NABP e-profile ID (e-PID) number, along with your date of birth (as “MM/DD”), in order to receive credit. No CPE credit will be issued or honored by paper certificate for programs attended after January 1st; however, you may receive, at the discretion of your CPE provider, a courtesy receipt of credit for informational purposes only. Licensed pharmacists and pharmacy technicians can obtain an e-PID number by registering with the CPE Monitor through the NABP website at www.nabp.net.

Financial Disclosures

All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Faculty

Christopher J. Campen, PharmD, BCPS, BCOP, has owned stock from AbbVie.

Wendy H. Vogel, MSN, FNP, AOCNP®, has been a part of speakers bureaus for Novartis, Celgene, Genentech, Lilly, Onyx/Bayer, and Regeneron/Sanofi.

Julie M. Vose, MD, MBA, has received research funding from Allos Therapeutics/Spectrum, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Incyte, Janssen Biotech, Pharmacyclics, and US Biotest.

Planners

Christopher J. Campen, PharmD, BCPS, BCOP, has owned stock from AbbVie.

Jeannine Coronna has nothing to disclose.

Heather M. Hylton, PA-C, has nothing to disclose.

Claudine Kiffer has nothing to disclose.

Sandra E. Kurtin, RN, MS, AOCN®, ANP-C, has been a consultant for Celgene, Onyx, Millennium, Incyte, and Novartis.

Terry Logan, CCMEP, has nothing to disclose.

Molly Thompson has nothing to disclose.

Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.

Wendy H. Vogel, MSN, FNP, AOCNP®, has been a part of speakers bureaus for Novartis, Celgene, Genentech, Lilly, Onyx/Bayer, and Regeneron/Sanofi.

Lead Nurse Planner

Rita Wickham, PhD, RN, AOCN®, has received honoraria from Genentech.

Content Reviewers

Peg Fields, RN, ACNP-BC, AOCNP®, has nothing to disclose. 

Ali McBride, PharmD, MS, BCPS, BCOP, has received honoraria from Amgen and Hospira. In addition, he has served on a speakers bureau for Millennium. 

Moshe Ornstein, MD, MA, has nothing to disclose. 

Disclaimer

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Meniscus Educational Institute educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Meniscus Educational Institute of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

This CME/CE/CEU accredited activity is jointly provided by:

     

  I confirm that I have read the above information.

If you do not want to earn credit but want to view the video, click here:




APSHO.org JADPRO Meniscus